Engineered DNA sequences target brain tumours while sparing healthy tissue: systemic breakthrough in precision oncology

Indigenous and traditional medical systems often treat cancer as a symptom of deeper ecological or spiritual disruptions, integrating plant-based therapies, dietary adjustments, and community support structures that Western oncology overlooks. The reliance on engineered DNA sequences mirrors a colonial approach to medicine, where synthetic interventions are privileged over time-tested, culturally adapted remedies. However, some indigenous communities have successfully combined traditional knowledge with modern techniques, such as the use of *Artemisia annua* (sweet wormwood) in TCM, which has inspired artemisinin-based cancer research.

The history of cancer treatment is marked by cycles of hype around 'miracle cures' that later proved ineffective or harmful, from radical mastectomies in the 19th century to the overpromising of chemotherapy in the 20th. The current focus on engineered DNA sequences echoes past failures to address the root causes of cancer, such as industrial pollution and socioeconomic disparities, which have been systematically ignored in favour of high-tech solutions. The pharmaceutical industry's role in shaping cancer research priorities dates back to the mid-20th century, when chemotherapy was aggressively marketed despite its limited efficacy in many cases.

Cross-culturally, cancer is often framed as a collective rather than an individual burden, with healing practices embedded in community rituals and environmental stewardship. In African traditional medicine, for example, cancer is sometimes treated through spiritual cleansing and herbal remedies that address both physical and metaphysical imbalances. The Western biomedical model, by contrast, isolates the disease from its social and ecological context, leading to fragmented and often ineffective care. Integrating these perspectives could yield more holistic and sustainable approaches to oncology.

Scientifically, the engineered DNA enhancer sequences represent a promising advancement in precision oncology, leveraging synthetic biology to selectively target tumour cells while minimising damage to healthy tissue. However, the scientific narrative often underplays the limitations of these therapies, such as the risk of off-target effects, the development of resistance, and the high costs that limit accessibility. Additionally, the focus on genetic engineering diverts attention from environmental carcinogens and lifestyle factors that contribute to tumour development, which are less amenable to technological fixes.

Artistic and spiritual traditions have long grappled with the metaphor of cancer as a destructive force that disrupts harmony, from the Greek humoral theory to Buddhist concepts of suffering and impermanence. In many cultures, cancer is not merely a physical ailment but a spiritual crisis requiring ritual and communal support, as seen in the use of music, dance, and prayer in healing practices. The Western biomedical model, however, often dismisses these dimensions as irrelevant, reducing cancer to a biochemical malfunction. Integrating artistic and spiritual perspectives could humanise oncology and address the emotional and existential dimensions of the disease.

Future modelling suggests that the next frontier in oncology will require a paradigm shift from reactive, high-tech interventions to proactive, systemic approaches that address environmental, social, and economic determinants of health. Scenarios that prioritise prevention, early detection, and equitable access to care—rather than expensive, late-stage treatments—could reduce the global cancer burden more effectively. Additionally, the integration of traditional and indigenous knowledge systems could yield novel therapeutic pathways that are both culturally appropriate and scientifically robust. The current focus on engineered DNA sequences risks locking in a high-cost, low-access model that exacerbates global health inequities.

Marginalised communities, including racial minorities, low-income populations, and indigenous groups, are disproportionately affected by cancer due to systemic barriers in healthcare access, environmental racism, and socioeconomic stressors. These communities are often excluded from clinical trials or underrepresented in research, leading to therapies that are less effective for them. The focus on engineered DNA sequences further marginalises the voices of those advocating for community-based, preventive care models that address the root causes of health disparities. Additionally, the high cost of these therapies ensures that they remain out of reach for the very populations most in need.